Authors:
Sirohi, B
Powles, R
Mehta, J
Treleaven, J
Raje, N
Kulkarni, S
Rudin, C
Bhagwati, N
Horton, C
Saso, R
Singhal, S
Parikh, P
Citation: B. Sirohi et al., The implication of compromised renal function at presentation in myeloma -Similar outcome in Patients who receive high-dose therapy: A single-centerstudy of 251 previously untreated patients, MED ONCOL, 18(1), 2001, pp. 39-50
Authors:
Sirohi, B
Powles, R
Kulkarni, S
Rudin, C
Saso, R
Lal, R
Singhal, S
Mehta, J
Horton, C
Treleaven, J
Citation: B. Sirohi et al., Comparison of new patients with Bence-Jones, IgG and IgA myeloma receivingsequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria, BONE MAR TR, 28(1), 2001, pp. 29-37
Authors:
Sirohi, B
Powles, R
Kulkarni, S
Rudin, C
Saso, R
Rigg, A
Horton, C
Singhal, S
Mehta, J
Treleaven, J
Citation: B. Sirohi et al., Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma, BR J CANC, 85(3), 2001, pp. 325-332
Authors:
Singhal, S
Powles, R
Treleaven, J
Kulkarni, S
Sirohi, B
Horton, C
Millar, B
Shepherd, V
Tait, D
Saso, R
Rowland, A
Long, S
Mehta, J
Citation: S. Singhal et al., A low CD34(+) cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34(+) cells/kg be considered the minimum threshold?, BONE MAR TR, 26(5), 2000, pp. 489-496
Authors:
Powles, R
Sirohi, B
Kulkarni, S
Bhagwati, N
Saso, R
Raje, N
Horton, C
Singhal, S
Mehta, J
Treleaven, J
Citation: R. Powles et al., Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients, BONE MAR TR, 25(9), 2000, pp. 949-956
Authors:
Vaidya, SJ
Atra, A
Bahl, S
Pinkerton, CR
Calvagna, V
Horton, C
Milan, S
Shepherd, V
Brain, C
Treleaven, J
Powles, R
Tait, D
Meller, ST
Citation: Sj. Vaidya et al., Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up, BONE MAR TR, 25(6), 2000, pp. 599-603
Authors:
Singhal, S
Powles, R
Kulkarni, S
Treleaven, J
Sirohi, B
Millar, B
Shepherd, V
Saso, R
Rowland, A
Long, S
Cabral, S
Horton, C
Mehta, J
Citation: S. Singhal et al., Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation, BONE MAR TR, 25(5), 2000, pp. 501-505
Authors:
Sirohi, B
Powles, R
Treleaven, J
Mainwaring, P
Kulkarni, S
Pandha, H
Bhagwati, N
Horton, C
Singhal, S
Mehta, J
Citation: B. Sirohi et al., The role of autologous transplantation in patients with multiple myeloma aged 65 years and over, BONE MAR TR, 25(5), 2000, pp. 533-539
Authors:
Kulkarni, S
Powles, R
Treleaven, J
Singhal, S
Horton, C
Sirohi, B
Bhagawati, N
Tait, D
Saso, R
Killick, S
Pinkerton, R
Atra, A
Meller, S
Mehta, J
Citation: S. Kulkarni et al., Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years, BONE MAR TR, 25(4), 2000, pp. 365-370
Authors:
Powles, R
Mehta, J
Kulkarni, S
Treleaven, J
Millar, B
Marsden, J
Shepherd, V
Rowland, A
Sirohi, B
Tait, D
Horton, C
Long, S
Singhal, S
Citation: R. Powles et al., Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial, LANCET, 355(9211), 2000, pp. 1231-1237
Authors:
Saso, R
Kulkarni, S
Mitchell, P
Treleaven, J
Swansbury, GJ
Mehta, J
Powles, R
Ashley, S
Kuan, A
Powles, T
Citation: R. Saso et al., Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma, BR J CANC, 83(1), 2000, pp. 91-94
Authors:
Kulkarni, S
Powles, R
Treleaven, J
Riley, U
Singhal, S
Horton, C
Sirohi, B
Bhagwati, N
Meller, S
Saso, R
Mehta, J
Citation: S. Kulkarni et al., Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants, BLOOD, 95(12), 2000, pp. 3683-3686
Authors:
Sumpter, K
Powles, RL
Raje, N
Ramiah, V
Kulkarni, S
Treleaven, J
Mainwaring, PN
Citation: K. Sumpter et al., Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma, LEUK LYMPH, 35(5-6), 1999, pp. 593-597
Authors:
Mehta, J
Powles, R
Treleaven, J
Swansbury, GJ
Kulkarni, S
Saso, R
Min, T
Singhal, S
Citation: J. Mehta et al., The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy, LEUK LYMPH, 34(5-6), 1999, pp. 553-560
Authors:
Singhal, S
Powles, R
Treleaven, J
Kulkarni, S
Horton, C
Mehta, J
Citation: S. Singhal et al., Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling, LEUK LYMPH, 34(3-4), 1999, pp. 287-294
Authors:
Singhal, S
Powles, R
Kulkarni, S
Treleaven, J
Saso, R
Mehta, J
Citation: S. Singhal et al., Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse, LEUK LYMPH, 32(5-6), 1999, pp. 505-512
Authors:
Singhal, S
Powles, R
Treleaven, J
Kulkarni, S
Horton, C
Mehta, J
Citation: S. Singhal et al., Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation, BONE MAR TR, 23(9), 1999, pp. 875-879
Authors:
DeLord, C
Treleaven, J
Shepherd, J
Saso, R
Powles, RL
Citation: C. Delord et al., Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia, BONE MAR TR, 23(5), 1999, pp. 523-525
Authors:
Sirohi, B
Powles, R
Mehta, J
Raje, N
Kulkarni, S
Ramiah, V
Saso, R
Horton, C
Bhagwati, N
Singhal, S
Treleaven, J
Citation: B. Sirohi et al., Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed diseaseentity with a new staging system, BR J HAEM, 107(3), 1999, pp. 656-666